Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Lykos Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT03537014
- Locations
- 🇺🇸
Trauma Research Foundation, Boston, Massachusetts, United States
🇨🇦Dr. Simon Amar, Inc., Montreal, Quebec, Canada
🇮🇱Sheba Fund for Health Services and Research, Tel HaShomer, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.